|Cardiovascular Area||Number of Drug Approvals||Total Enrollment, N||Women Enrolled, n||Percentage of Women Among Trial Participants, % (Range)||Percentage of Women Among Disease Population∗|
|Acute coronary syndrome/myocardial infarction||3||43,377||11,932||28 (26–28)||43|
|Atrial fibrillation||5||76,311||28,884||38 (35–47)||36; 49†|
|Coronary artery disease (including angina)||3||49,190||11,777||24 (24–25)||43|
|Heart failure||3||15,997||3,802||24 (22–40)||40; 53‡|
|Pulmonary arterial hypertension||7||3,763||2,907||77 (74–81)||57|
CVD = cardiovascular disease.
↵∗ References and calculations are presented in Online Tables 1 and 2.
↵† Gender-stratified prevalence of atrial fibrillation in a representative population was not available. Two percentages were provided; one based on age-adjusted prevalence using published population-based studies (36%) and the other based on a cohort of atrial fibrillation patients within Kaiser Permanente of Northern California (49%).
↵‡ Trials for heart failure drugs were conducted only among patients with reduced ejection fraction. Gender-stratified prevalence of heart failure with reduced ejection fraction was not available in a representative population. Two percentages were provided; one based on prevalence of all heart failure patients in the United States (53%) and the other based on the Framingham cohort with heart failure with reduced ejection fraction (40%).